Given that the overactivation of pathways, such as the JAK-STAT pathway, is predominantly involved in ML-DS pathogenesis, inhibition of these pathways, e.g., using JAK1/2 inhibitors, may play a crucial role in the therapeutic approach of ML-DS patients with activating JAK-STAT mutations [22]. Here, JAK1 is linked to Dravet syndrome.